Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,201–2,300 of 3,636
Obicetrapib–ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease
Lee, S., & Kim, B. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00827-x · Cited by 3
van Bruggen, F. H., & Diamond, D. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103569 · Cited by 4
“In the FOURIER and ODYSSEY OUTCOMES trials, these PCSK9 inhibitors achieved remarkably low LDL-C levels (30 and 38 mg/dL, respectively), while also significantly reducing Lp(a) levels [91,92].”
Kaser, S., Dobrev, D., Rocca, B., Kaski, J. C., Agewall, S., & Drexel, H. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf023 · Cited by 3
Hodeda, L., Eisen, A., Rotholz, A., Kornowski, R., & Gurevitz, C. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101022 · Cited by 7
“However, in both phase 3 clinical outcomes randomized controlled trials, similarly to other landmark cardiovascular trials, women were underrepresented, accounting for only about 25 % of the total cohort [7,8].”
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Ponnana, S. R., Mahalwar, G., Holtrop, J., et al. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100580 · Cited by 3
“…when compared with placebo in patients who were initiated on treatment within 30 days of MI. Low Dose Colchicine in chronic coronary disease (LoDoCo2) Trial also reported improved outcomes with colchicine 0.5 mg daily in patients with chronic coronary disease when compared to placebo [8,9].”
InfluentialRay, K. K., Szarek, M. J., Bhatt, D. L., Bittner, V., Fazio, S., Goodman, S. G., Harrington, R. A., Jukema, J. W., White, H. D., Steg, P. G., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.043 · Cited by 5
Self-citationHwang, S., Karhunen, V., Patel, A., Lockhart, S. M., Carter, P. R., Whittaker, J. C., & Burgess, S. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyaf223 · Cited by 3
Medical therapeutics: mortality effects, uncertainty, and informed consent
Nunes, J. P. L. (2019) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000035 · Cited by 3
“Alirocumab (also a proprotein convertase subtilisin-kexin type 9 inhibitor), however, did show a decrease in mortality of patients after acute coronary syndrome, but this effect was limited to patients with a baseline LDL-C of 100mg/dL or more.(17) Lipid-lowering therapy shows us, once again, that a decrease in cardia…”
BackgroundBiometrische Aspekte in Ethikkommissionen
Schlattmann, P., Scherag, A., Rauch, G., & Mansmann, U. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02951-9 · Cited by 5
A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
Alali, R. A. (2019) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2019.01.31812 · Cited by 3
“The latter was withdrawn from development in 2016 (Bove et al., 2019; Schwartz et al., 2018; Sabatine et al., 2017; Pitts and Eckel, 2014).”
BackgroundCan one overcome “unhealthy genes”?
Lazarte, J., & Hegele, R. A. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0099-2 · Cited by 3
Expert group from the Spanish Arteriosclerosis Society, Pedro‐Botet, J., López‐Miranda, J., Badimón, L., Civeira, F., Guijarro, C., Millán, J., Mostaza, J. M., Pintó, X., Valdivielso, P., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00376-y · Cited by 3
Rodríguez, Á. D., & Morató, T. M. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.10.004 · Cited by 7
The need to improve cardiac care after acute coronary syndrome
Kolovou, G. D. (2019) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2019.12.002 · Cited by 3
Levintow, S. N., Reading, S. R., Saul, B., Yu, Y., Reams, D., McGrath, L. J., Philip, K. J., Dluzniewski, P. J., & Brookhart, M. A. (2020) · Clinical Epidemiology · doi:10.2147/clep.s259757 · Cited by 4
Tunoa, J., Billups, S. J., Lowe, R. N., & Saseen, J. J. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.09.001 · Cited by 3
Gil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología · doi:10.1016/j.nrl.2020.11.006 · Cited by 5
Use of cardiovascular imaging in risk restratification of the diabetic patient
Bellinge, J. W., Lee, S. C., & Schultz, C. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000611 · Cited by 3
Astigmatism among children in Jeddah, Saudi Arabia: prevalence and associated factors
Basheikh, A. A., Howldar, S., Basendwah, M., Baqais, R. T., Bamakrid, M., & Alhibshi, N. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93976 · Cited by 3
Use of eye drops self-medication in Aseer region, Southern Saudi Arabia
Alamri, A. M., Asiri, R., Al-Nami, A., Hijazi, R., & Almobty, L. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93984 · Cited by 2
Kalashnikov, V. Y., & Michurova, M. S. (2021) · Kardiologiia · doi:10.18087/cardio.2021.1.n1148 · Cited by 3
Beyerle, A., Greene, B., Dietrich, B., Kingwell, B. A., Panjwani, P., Wright, S. D., & Herzog, E. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115557 · Cited by 3
Cardiovascular Disease Epidemiology and Risk Factors: General Concepts
Toth, P. P. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-62632-7_1 · Cited by 6
Jawade, S. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i39b32206 · Cited by 3
PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
Блохина, А. В., Ershova, A. I., Limonova, A. S., Викторовна, К. О., Meshkov, A. N., & Drapkina, O. M. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-12-01 · Cited by 3
Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review
Hassen, L. J., Scarfone, S. R., & Milks, M. W. (2022) · Geriatrics · doi:10.3390/geriatrics7020038 · Cited by 5
“These medications were studied in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) and Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome (ODYSSEY OUTCOMES) trials, which showed that the PCSK9 inhibitors, when added to statin therapy for se…”
MethodNa, H. R., Kwon, O., Kang, J. K., Kim, Y. H., & Lim, J. Y. (2022) · Trials · doi:10.1186/s13063-022-06398-3 · Cited by 4
Diabetes: how to manage cardiovascular risk in secondary prevention patients
Anderson, S. L., & Marrs, J. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-10-1 · Cited by 3
Citarella, A., Cammarota, S., Bernardi, F. F., Caliendo, L., D’Andrea, A., Fimiani, B., Fogliasecca, M., Pacella, D., Pagnotta, R., Trama, U., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154344 · Cited by 3
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 4
Zhao, Y., Chen, W., Yan, X.-Y., Liu, K., Liu, G., & Yang, P. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i32.11955 · Cited by 3
Yu, Q., Yang, J., Wang, J., et al. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24821 · Cited by 3
“In the context of cellular component (CC) pathways, through bioinformatic profiling via the GO and DAVID databases, the genes connected to differentially methylated sites could be arranged into 10 groups: (1) cell projection (GO:0042995); (2) cytoplasm (GO:0005737); (3) cell junction (GO:0030054); (4) neuron part (GO:…”
BackgroundMethodTorres, J. M. R., López-Téllez, A., Ariza, M. J., Rioja, J., García‐Casares, N., Rodríguez, E. E. G., García, J. A. R., Chaparro, M. Á. S., Barbancho, M. Á., & Valdivielso, P. (2023) · BMC Family Practice · doi:10.1186/s12875-023-01997-8 · Cited by 4
Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin
Susekov, A. V. (2023) · Kardiologiia · doi:10.18087/cardio.2023.2.n2407 · Cited by 4
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
Rakočević, J., Dobric, M. R., Vučić, R. M., Furtula, M., Zaletel, I. V., Milutinović, K., Ilijevski, A., Labudović‐Borović, M., Tomasevic, M. V., & Bajčetić, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24066012 · Cited by 5
“Long-term administration of alirocumab in patients with recent acute coronary syndrome and elevated LDL cholesterol levels led to 15% risk reduction in MACE compared to placebo [7].”
BackgroundSchiele, F., Sabouret, P. F., Puymirat, É., ABDENNBI, K., LEBEAU, F., MELTZ, M., Kownator, S., & Angoulvant, D. (2023) · Panminerva Medica · doi:10.23736/s0031-0808.22.04799-1 · Cited by 3
Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
Wang, W., Luo, R., Pei, D. A., Huang, Q., Jin, X., Wu, Y., Xie, M., Wang, S., Sui, X.-Q., & Shen, B. (2023) · Medicine · doi:10.1097/md.0000000000033026 · Cited by 3
“[29] A clinical study has revealed that PCSK9 inhibition may confer benefits during ACS through LDL-dependent mechanism.[11] Intriguingly, beyond its effects on LDL metabolism, preliminary results suggest PCSK9 as a positive modulator of platelet activation in in vitro and in vivo models.”
BackgroundStabilization of vulnerable plaque in the ACS patient: evidence from HUYGENS studies
Zanda, G., & Varbella, F. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad013 · Cited by 4
“The introduction of more potent lipid-lowering therapies such as PCSK9 inhibitors allowed to obtain a greater reduction of LDL-C and have proven to reduce cardiovascular events in addition to statin therapy in patients who had suffered ACS.1,2 The phenomenon of plaque stabilization and regression has been investigated…”
BackgroundSerum and genetic markers related to rapid clinical progression of coronary artery disease
Camarero, T. G., Remuzgo‐Martínez, S., Genre, F., López‐Mejías, R., Pulito‐Cueto, V., Fernández, G. V., Hwang, D.-H. L., Laso, F. S., Ongay, A. G., González-Gay, M. Á., et al. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.04.005 · Cited by 3
Luca, L. D., Riccio, C., Navazio, A., Valente, S., Cipriani, M., Corda, M., Nardo, A. D., Francese, G. M., Napoletano, C., Tizzani, E., et al. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad100 · Cited by 3
“51,52 A recent meta-analysis that included 39 randomized clinical trials and ∼ 66 500 patients treated with alirocumab or evolocu-mab and followed up for ∼ 2 years confirmed that PCSK9 inhibition is associated with a significant reduction in myocardial infarction, ischaemic stroke, and coronary…”
BackgroundMethodIn-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
Canonico, M. E., Hess, C. N., & Cannon, C. P. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01112-3 · Cited by 4
Thoughts on Future Trends in Cardiology
Ma, C., & Han, Y. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000001 · Cited by 3
Park, J. K., Balarbar, N., & Agarwala, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01911-9 · Cited by 4
Camarero, T. G., Remuzgo‐Martínez, S., Genre, F., López‐Mejías, R., Pulito‐Cueto, V., Veiga, G., Hwang, D.-H. L., Laso, F. S., Ongay, A. G., González-Gay, M. Á., et al. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.04.009 · Cited by 3
Hlinomaz, O., Motovska, Z. J., Kala, P., Hromádka, M., Přeček, J., Mrózek, J., Červinka, P., Kettner, J., Matějka, J., Zohor, A., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.08.009 · Cited by 3
Jeong, C., Kim, B., Kim, J., Baek, H.-S., Kim, M. K., Sohn, T. S., Baek, K., Song, K., Son, H.-S., Han, K., et al. (2023) · Endocrine Connections · doi:10.1530/ec-23-0142 · Cited by 4
“Moreover, recent research studies on PCSK-9 inhibitors have shown the concept of ‘the lower, the better’ without an apparent lower threshold for LDL-C level for secondary prevention (6, 7, 8).”
BackgroundResultLuo, T., Yuan, J., Qiu, L., Liu, D., Xun, J., Hu, P. F., Yan, P., Wang, Q., & Yan, H. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.08.166 · Cited by 3
The Role of Lipid-Lowering Therapy in Post-Stroke Patients: Update and Recommendations
Avenatti, E., Avila, J. C., Heidari, B., Hagan, K., Taha, M. B., & Nasir, K. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01159-2 · Cited by 6
“They showed potent lipid-lowering effects in two major trials, with significant impact on cardiovascular outcomes [24, 25].”
BackgroundMethodMcKoy, J. N., Kalich, B. A., Greene, L., Mackey, R. H., Rosenthal, N. A., Khan, Y. M., Wójcik, C., Jones, J., & Carabuena, L. A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02716-6 · Cited by 3
Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)
Arnold, N., & Koenig, W. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01163-6 · Cited by 3
Park, J., Song, J., Bae, Y.-H., Cho, Y.-H., Son, B.-J., Kim, H.-J., Choi, K., Nam, J., Lee, C., Son, J., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.11.067 · Cited by 3
How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams, T., Nelson, A. J., & Nicholls, S. J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01188-5 · Cited by 3
“Clinical trials have subsequently demonstrated the clinical benefit of adding either ezetimibe [7] or proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors [8, 9] to statin therapy.”
BackgroundManaging hypercholesterolaemia
Nelson, A. J., & Nicholls, S. J. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.006 · Cited by 4
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups
Wu, N., Li, Z.-F., Lu, M.-Y., & Li, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2321374 · Cited by 4
“This trial concluded that alirocumab reduced recurrent ischemic cardiovascular events in patients with prior ACS on high-intensity statins [80].”
BackgroundClosing the sex gap in cardiovascular mortality by achieving both horizontal and vertical equity
Bugiardini, R., & Gulati, M. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117500 · Cited by 4
Primary Prevention of Cardiovascular Disease in Women
Shahid, I., Avenatti, E., Titus, A., Al-Kindi, S. G., & Nasir, K. (2024) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1313 · Cited by 8
Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies
Branigan, P., Duong, Y. V., Abdulfattah, A., Sabu, J., Mallappallil, M. C., & John, S. (2024) · Cureus · doi:10.7759/cureus.60877 · Cited by 8
“The ODYSSEY OUTCOMES trial showed that adding alirocumab to maximally tolerated statin therapy reduces the risk of CVD [130].”
MethodSong, R., Li, J., Xiong, Y., Huang, H., Liu, X., & Li, Q. (2024) · Medicine · doi:10.1097/md.0000000000038360 · Cited by 3
Li, W., Sun, L., & Yan, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1375040 · Cited by 5
Zheng, J., Li, T., Hu, F., et al. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.07.030 · Cited by 3
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Bertolet, B. D., Cabral, K. P., Sullenberger, L. E., McAlister, J., Sandroni, T., & Patel, D. S. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00665-1 · Cited by 4
“Presently, the addition of ezetimibe and anti-PCSK9 mAbs to statins, and the use of bempe-doic acid in statin-intolerant patients, have been shown to improve CV outcomes [19, 22, 24, 25].”
BackgroundOu, Z., Wang, F., Chen, Y., Liu, X., Ran, B., Yin, Y., & Cui, K. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07622-9 · Cited by 6
Tse, H., Chang, H., Colquhoun, D., Kim, J., Poh, K. K., Kostner, K., Hutayanon, P., Cho, M., Lange, J. L., Kodiappan, K., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00384-3 · Cited by 5
“Consistent with previous clinical trials of PCSK9i [11, 26], lin‑ ear CV benefits were observed with even lower LDL‑”
Huang, Z., Zhang, W., Wang, D.-Z., Zhang, Y., Duan, Y.-B., He, X., Gao, Y.-X., Jia, Z.-N., & Qian, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2446407 · Cited by 4
“These drugs have been shown to significantly reduce LDL-C levels and cardiovascular risk, but require subcutaneous injections every two weeks or every month, which raises concerns about patient compliance [11,12].”
Yao, Y., Qiu, Q., Wang, Z., Xu, S.-K., & Lv, Q. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00719-4 · Cited by 5
“Landmark trials such as FOURIER and ODYSSEY OUTCOMES have consistently shown LDL-C reductions of 50–63% when PCSK9 inhibitors are added to statin therapy [43, 44].”
InfluentialBrockmeyer, M., Fell, M., Parco, C., Hoss, A., Vargas, K. G., Wies, E., Lin, Y., Heinen, Y., Chernyak, N., Icks, A., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04599-7 · Cited by 4
“Given that several drug classes, such as high-intensity statins [26], ezetimibe [27], bempedoic acid [28], and PCSK9 inhibitors [29, 30], improve patient outcomes and are capable of lowering LDL-C to target patients, health services research on LDL-C risk factor management is urgently needed to…”
Mehilli, J., Eckardt, L., Laufs, U., Boer, J., Birkemeyer, R., Frantz, S., Schächinger, V., Mahfoud, F., Perings, C., Ghanem, A., et al. (2025) · Die Kardiologie · doi:10.1007/s12181-025-00744-w · Cited by 3
Sharma, T., Maehara, A., Mæng, M., Kjøller‐Hansen, L., Engstrøm, T., Ben‐Yehuda, O., Matsumura, M., Fröbert, O., Persson, J., Wiseth, R., et al. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200440 · Cited by 3
“Therapeutic advances with statins and PCSK9 inhibitors have shown marked reduction of low-density lipoprotein cholesterol (LDL-C) and subsequent MACE [30,31].”
Hu, X., Wang, Z., Liu, J., et al. (2025) · International Journal of Stroke · doi:10.1177/17474930251351103 · Cited by 3
Bejjani, A., Khairani, C. D., Krishnathasan, D., Rizzo, S. M., Sato, A., Bacare, B., Scimeca, G., Tristani, A., Armero, A., Porio, N. D., et al. (2025) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf109 · Cited by 7
Werba, J. P., Vigo, L., Veglia, F., Marenzi, G., Tremoli, E., & Baldassarre, D. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1436 · Cited by 3
Kobalava, J. D., Gurevich, V. S., Galyavich, A. M., Каминный, А. И., Кашталап, В. В., Mareev, V. Y., Susekov, A. V., & Иосифович, Ш. И. (2019) · Kardiologiia · doi:10.18087/cardio.n581 · Cited by 5
News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.09.013 · Cited by 3
A tip of the CAP1 to cholesterol metabolism
Dron, J. S., & Hegele, R. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz771 · Cited by 3
Uso adecuado de las estatinas de alta intensidad
Masson, W. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.24 · Cited by 4
“Esto último se vuelve a demostrar en los últimos ensayos clínicos que agregaron otros fármacos (ezetimibe e inhibidores de la PCSK9) a pacientes en prevención secundaria medicados con estatinas que alcanzaron niveles extremadamente bajos de C-LDL(26-29).”
BackgroundLipoprotein(a), the rediscovered risk factor, or how to get “back to the future”
Sabouret, P. F., Angoulvant, D., & Ray, K. K. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.03.008 · Cited by 2
Masana, L., López‐Miranda, J., Civeira, F., Reinares, L., Guijarro, C., Plana, N., Cuenca, R., Sánchez, D. L., Hernández, J. L., de Andrés, R., et al. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.02.003 · Cited by 5
LDL-cholesterol reduction in chronic kidney disease: options beyond statins
Goonasekera, M. A., Mafham, M. M., & Haynes, R. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000628 · Cited by 3
“ODYSSEY OUTCOMES, 2018 [10] Recent ACS, n1⁄418 924, eGFR<30 Alirocumab vs.”
BackgroundInclisiran, the billion-dollar drug, to lower LDL cholesterol – is it worth it?
Doggrell, S. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1799978 · Cited by 3
Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients
Clark, D., Puri, R., & Nissen, S. E. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1833716 · Cited by 4
Škorić, B. (2021) · Cardiologia Croatica · doi:10.15836/ccar2021.87 · Cited by 4
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 4
Sykes, R., Briscoe, M., Krysztofiak, T., Peck, O. H., Mangion, K., & Berry, C. (2021) · Open Heart · doi:10.1136/openhrt-2021-001633 · Cited by 3
“COVID-19 was a primary or secondary diagnosis in 35 (16.7”
InfluentialDerosa, G., Maffioli, P., D’Angelo, A., Girola, A., Colombo, E., Fiorenza, A. M., Ceballos-Macías, J. J., Sanchez, C. L., Raddino, R., Pasini, G. F., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001237 · Cited by 4
Barrios, V., Escobar, C., Arrarte, V., Bravo, M., del Campo, A., Hidalgo, R., Recasens, L., & Cequier, A. R. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.11.003 · Cited by 4
Adeli, K., Xiao, C., Higgins, V., Taher, J., Farr, S., & Lewis, G. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824048-9.00002-x · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.
Engler, R. J. M., Brede, E., Villines, T. C., & Vernalis, M. (2019) · PubMed · Cited by 4
Langslet, G., Hovingh, G. K., Guyton, J. R., Baccara‐Dinet, M. T., Letierce, A., Manvelian, G. Z., & Farnier, M. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06984-0 · Cited by 3
Malvandi, A. M., Canclini, L., Alliaj, A., Magni, P., Zambon, A., & Catapano, A. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1801628 · Cited by 3
“7%, thus reducing up to 15% cardiovascular risk if compared with the placebo group [76].”
BackgroundWeir (2020) · The Journal of Family Practice · doi:10.12788/jfp.0068 · Cited by 3
Recognition and Management of Hypoglycemia
Shubrook (2020) · The Journal of Family Practice · doi:10.12788/jfp.0069 · Cited by 3
Bempedoic Acid: A New Avenue for the Treatment of Dyslipidemia
Smith, W., Cheng-Lai, A., & Nawarskas, J. J. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000401 · Cited by 3
Zafrir, B., Hislop, E., Volis, I., & Saliba, W. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab724.2938 · Cited by 4
Kunimura, A., Miura, K., Segawa, H., Torii, S., Kondo, K., Hisamatsu, T., Kadota, A., Fujiyoshi, A., Yano, Y., Nakagawa, Y., et al. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63549 · Cited by 3
Risk stratification of patients with INOCA: is perfusion PET imaging the game winner?
Liga, R., & Gimelli, A. (2022) · Journal of Nuclear Cardiology · doi:10.1007/s12350-022-03169-0 · Cited by 3
Tsimikas, S., Bhatia, H. S., & Erlinge, D. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.06.005 · Cited by 3
PCSK9 Inhibition for Therapeutic Decision-Making
Weintraub, W. S., & Boden, W. E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.037 · Cited by 3
Lavere behandlingsmål for LDL-kolesterol bør innføres
Retterstøl, K., Munkhaugen, J., Ingul, C. B., Grimsmo, J., Kask, A., Schirmer, H., Semb, A. G., & Solberg, E. E. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.20.0761 · Cited by 3
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

